Research centre

Last updated on: 19/07/2016

1. Contact details{View data sources/studies associated with this centre}

Name of organisation

1) Department/Research group

2) Organisation/affiliationNetherlands Pharmacovigilance Centre Lareb

Short Name in the inventoryNetherlands Pharmacovigilance Centre Lareb

Website/Homepagewww.lareb.nl

Administrative Contact

Title Professor

Last name van Puijenbroek

First name Eugene

Address line 1Goudsbloemvallei 7

Address line 2

Address line 3

City's-Hertogenbosch

Postcode5237MH

CountryNetherlands

Phone number (incl. country code)31-73-6469700

Alternative phone number

Fax number (incl. country code)31-73-6426136

Email address e.vanpuijenbroek@lareb.nl

Scientific Contact

Title Professor

Last name van Puijenbroek

First name Eugene

Address line 1Goudsbloemvallei 7

Address line 2

Address line 3

City's-Hertogenbosch

Postcode5237MH

CountryNetherlands

Phone number (incl. country code)31-73-6469700

Alternative phone number

Fax number (incl. country code)31-73-6426136

Email address e.vanpuijenbroek@lareb.nl

Alternative Scientific Contact

Title Dr

Last name Kant

First name Agnes

Address line 1Goudsbloemvallei 7

Address line 2

Address line 3

City's-Hertogenbosch

Postcode5237MH

CountryNetherlands

Phone number (incl. country code)31-73-6469700

Alternative phone number

Fax number (incl. country code)31-73-6426136

Email address a.kant@lareb.nl

2. Description

The Netherlands Pharmacovigilance Centre Lareb collects and analyses reports of suspected adverse drug reactions reported by health care professionals, patients and market authorisation holders in the Netherlands. Lareb informs both government and health professionals about important new signals. The Lareb database presently contains over 100.000 reports. Reports are reviewed on a case-by-case basis. Potential signals undergo further analysis. Statistical techniques are used to support the signal detection process. In addition Lareb gathers information of adverse drug reactions by means of an intensive monitoring system. In his system patients are included when they collect the drug under investigation in the pharmacy for the first time. After on-line registration, the patient will receive questionnaires via e-mail at specific points in time asking for experiences with the drug, including adverse drug reactions (ADRs) and other information related to drug use.